Breast Cancer Clinical Trial
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic). Both the unmodified vaccination measles virus (MV-Edm) and this modified virus (MV-s-NAP) have been shown to multiply in and destroy breast cancer cells in the test tube and in research mice. MV-s-NAP has been altered by having an extra gene (piece of deoxyribonucleic acid [DNA]) so that virus can make a protein called helicobacter pylori neutrophil activating protein (NAP) which is normally expressed in inflammatory reactions. Monitoring blood, urine, tissue, and throat swab samples, and using imaging tests may help to determine whether MV-s-NAP has any impact on the amount of disease present in metastatic breast cancer patients.
I. To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measles virus genetically engineered to express NAP (oncolytic measles virus encoding helicobacter pylori neutrophil-activating protein (modified virus strain neutrophil activating protein [MV-s- NAP) in patients with metastatic breast cancer.
II. To determine the safety and toxicity of one-time intratumoral administration of MV-s-NAP in patients with metastatic breast cancer.
III. To determine the safety and toxicity of serial intratumoral administration of MV-s-NAP in patients with metastatic breast cancer.
I. To assess in a preliminary fashion antitumor efficacy of this approach by following radiographic response and time to progression.
Ia. Response at and away from the site of MV-s-NAP administration will be evaluated.
I. To assess viremia, viral replication, and measles virus shedding/persistence following intratumoral administration.
II. To determine the time course of viral infection and viral gene expression in treated/untreated lesions.
III. To determine immune response development against MV, the therapeutic s-NAP transgene, and the tumor.
IV. To obtain preliminary assessments of PD-L1 expression in tumor cells and tumor infiltrating lymphocytes (TILs).
Patients receive MV-s-NAP intratumorally (IT) on day 1 in the absence of disease progression or unacceptable toxicity. After 1 cycle of treatment, patients who experience disease progression proceed to follow-up. Patients who achieve complete response (CR), partial response (PR), or stable disease (SD) receive MV-s-NAP IT every 21 days for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months during year 1, and then every 6 months during year 2.
Pathologically confirmed invasive breast adenocarcinoma with documented estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) status and radiographic evidence of distant metastatic disease.
Radiographic evidence of distant metastatic disease (using 7th edition American Joint Committee on Cancer [AJCC] criteria) with two discrete sites of measurable disease
No available standard therapy that is considered curative.
NOTE: Patients with ER/PR positive, HER2 negative breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease and no longer be candidates for standard endocrine therapy (including combination therapy that includes palbociclib or everolimus). Patients with HER2 positive breast cancer irrespective of ER/PR status must have received or no longer be candidates for standard HER2 directed therapy (i.e., trastuzumab, pertuzumab, trastuzumab, emtansine, and lapatinib). Patients with ER/PR/HER2 negative breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease
At least one site of recurrent/metastatic disease that measures > 1 cm in greatest dimension (> 2 cm for lung lesions) and is amenable to safe percutaneous intratumoral administration of MV-s-NAP as determined by an interventional radiologist.
NOTE: In Phase I of the trial (single injection), only one lesion will be injected. In Phase II of the trial (3, every 3 weeks [Q3weekly] injections), the same lesion will be injected unless the interventional radiologist determines that lesion is not amenable to reinjection, in which case another lesion (if present and measuring > 1 cm in greatest dimension [> 2 cm for lung lesions]) will be injected
Absolute neutrophil count (ANC) >= 1500/uL (=< 7 days prior to registration)
Platelets (PLT >= 100,000/uL) (=< 7 days prior to registration)
Total bilirubin =< institutional upper limit of normal (=< 7 days prior to registration)
Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN) (=< 7 days prior to registration)
Creatinine =< 1.5 x ULN (=< 7 days prior to registration)
Hemoglobin >= 9.0 g/dL (=< 7 days prior to registration)
Negative pregnancy test done =< 7 days prior to registration (for women of childbearing potential only)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Ability to provide informed written consent
Willingness to return to the Mayo Clinic enrolling institution for follow-up
Willingness to provide biologic samples for correlative research purposes
Life expectancy >= 12 weeks
Concomitant administration of a bone modifying agent (e.g., zoledronic acid or denosumab) for the prevention or management of skeletal related events in patients with bone metastases and documentation of tolerability with prior exposures
Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
Clinical or radiographic suspicion of impending visceral crisis due to invasion or compression by tumor
Active infection =< 5 days prior to registration
History of tuberculosis or history of tuberculin skin test positivity
History of other malignancy =< 5 years except for non-melanoma skin cancer or carcinoma in situ of the cervix
Any of the following prior therapies:
Chemotherapy =< 3 weeks prior to registration
Immunotherapy =< 4 weeks prior to registration
HER2 directed therapy =< 3 weeks prior to registration
Targeted therapy =< 2 weeks prior to registration (e.g., CDK4/6 inhibitors, everolimus)
Investigational agent =< 4 weeks prior to registration
Any viral or gene therapy prior to registration
Failure to fully recover from acute, reversible effects of prior systemic therapy regardless of interval since last treatment
New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])
Untreated or progressive central nervous system (CNS) metastases
NOTE: Patients with a history of treated brain metastases (surgical resection, whole brain radiation, and/or stereotactic radiosurgery) are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days of study entry
Standing requirement for blood product support
Human immunodeficiency virus (HIV) positive test result or history of other immunodeficiency
History of organ transplantation
History of chronic hepatitis B or C
Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
Any concurrent medications that the principal investigator determines could interfere with the trial
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
Exposure to household contacts =< 15 months old or household contact with known immunodeficiency
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
History of receiving the measles vaccination with the "killed vaccine" between 1963-1967 without subsequent re-immunization (2 doses) with the active, live vaccination."
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.